LIVE
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point. Track Caplin Point Laboratories Limited's live NSE:CAPLIPOINT share price ₹2,583.10 (+3.04%), market cap ₹₹196B, P/E 30.7. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for CAPLIPOINT — real-time NSE India stock intelligence.
Open
₹2,516.80
High
₹2,586.50
Low
₹2,496.20
Prev. Close
₹2,507.00
52W High
₹2,699.00
52W Low
₹1,500.30
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point
Key Takeaway
Caplin Point Laboratories Limited is rated none with a P/E of 30.7x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Caplin Point Laboratories Limited fairly valued right now?
Because a P/E of 30.7x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Caplin Point Laboratories Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
600 Cr
Revenue
170 Cr
Net Profit
19.9%
ROE
0%
ROCE
84.06
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 1,454 | 1,680 | 1,937 | 2,187 | 2,155 |
| Net Profit | 376 | 457 | 536 | 641 | 630 |
| ROE (%) | — | — | — | 19.9% | 19.9% |
| EPS (₹) | — | — | — | 84.06 | 84.06 |
| Debt/Equity | — | — | — | 0.1 | 0.1 |